Company Name, Ticker, Customers, else..

Prime Medicine Inc (NASDAQ: PRME)

Sector • Healthcare Industry • Biotechnology & Pharmaceuticals

Industry • Biotechnology & Pharmaceuticals

Sector • Healthcare

Prime Medicine Inc 's

Name: Prime Medicine Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

PRME Sales vs. its Competitors Q1 2026

Comparing the current results to its competitors, Prime Medicine Inc reported Revenue decrease in the 1 quarter 2026 year on year by -41.13 %, despite the revenue increase by the most of its competitors of 1.52 %, recorded in the same quarter.

• List of PRME Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Prime Medicine Inc , faster than the decline experienced by the competitors recorded a net loss, as well as most of its competitors.

<< PRME Stock Performance Comparisons

<< See the full list of PRME competitors

Overall company Market Share Q1 2026

Overall company, revenue fell by -41.13 % and company lost market share, to approximately 0.01 %. << More on PRME Market Share.

*Market share is calculated based on total revenue.

News about Prime Medicine Inc Contracts

Prime Medicines Advancements in Genetic Editing Highlight New Potential for Treating Wilsons Disease,

October 15, 2024
Prime Medicine s Pioneering Approach to Wilson s Disease: A Step Toward Transformative Genetic Therapies In a significant announcement that underscores the potential for revolutionary advancements in genetic therapies, Prime Medicine Inc. a biotechnology firm listed on Nasdaq with the ticker PRME, has revealed plans to showcase new, compelling preclinical data for Wilson s Disease at upcoming notable scientific conventions. This disclosure marks another critical milestone in Prime Medicine s effort to develop one-time curative genetic treatments using its cutting-edge Prime Editing technology. Showcasing InnovationsThe Cambridge, Massachusetts-based biotech company will present its data at the European Socie...

PRME's Stock Performance relative to its Competitors

Publicly Traded Peers of Prime Medicine Inc

Editas Medicine Inc
Share Performance

+16.19%

This Quarter

Editas Medicine Inc

Profile

Editas Medicine Inc.'s business model revolves around developing and commercializing transformative genome editing technologies to treat serious diseases.

More about Editas Medicine Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 316.150 mill.	$ 38.693 mill.	$ -108.954 mill.

Meiragtx Holdings Plc
Share Performance

+47.92%

This Quarter

Meiragtx Holdings Plc

Profile

MeiraGTx Holdings Plc is a biotechnology company focused on developing gene therapies for inherited and acquired diseases. They leverage their proprietary technology to develop and commercialize innovative treatments that address unmet medical needs.

More about Meiragtx Holdings Plc's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 1,302.956 mill.	$ 397.501 mill.	$ 78.931 mill.

Metagenomi Therapeutics Inc
Share Performance

-12.03%

This Quarter

Metagenomi Therapeutics Inc

Profile

The company conducts research and development in genome editing technology and clinical trials.

More about Metagenomi Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 44.060 mill.	$ - mill.	$ -93.462 mill.

Molecular Partners Ag
Share Performance

+7.94%

This Quarter

Molecular Partners Ag

Profile

Molecular Partners Ag is a biotechnology company that operates on an innovative business model focused on the development of therapeutic drugs. The company utilizes its proprietary DARPin technology platform to create a pipeline of potential treatments for various diseases. Molecular Partners Ag primarily collaborates with strategic partners, including pharmaceutical companies, to advance its drug candidates through preclinical and clinical development stages.

More about Molecular Partners Ag's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 162.130 mill.	$ - mill.	$ -86.357 mill.

Moderna Inc
Share Performance

+170.24%

30 Days

Moderna Inc

Profile

Moderna Inc's business model revolves around the development and commercialization of mRNA-based therapeutics and vaccines. They focus on using messenger RNA (mRNA) technology to create drugs that can help prevent and treat various diseases.

More about Moderna Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 57,928.900 mill.	$ 2,228.000 mill.	$ -3,151.000 mill.

49 more competitors available

Sources: Prime Medicine Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Monday, September 7, 2026 5:59 PM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Prime Medicine Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.